Stroke, Vol 20, 295-298, Copyright © 1989 by American Heart Association
SJ Phillips
Despite the lack of evidence of its efficacy, heparin therapy has been
recommended for selected patients with ischemic stroke syndromes. However,
heparin has procoagulant effects on platelet function and a propensity to
produce serious side effects. When these factors are considered, heparin
loses its appeal as a therapeutic agent for patients with acute focal
cerebral ischemia.
ARTICLES
An alternative view of heparin anticoagulation in acute focal brain ischemia
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
This article has been cited by other articles:
![]() |
R. Kay, K. S. Wong, Y. L. Yu, Y. W. Chan, T. H. Tsoi, A. T. Ahuja, F. L. chan, K. Y. Fong, C. B. Law, A. Wong, et al. Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke N. Engl. J. Med., December 14, 1995; 333(24): 1588 - 1594. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Counsell, C. Warlow, P. Sandercock, H. Fraser, and J. van Gijn The Cochrane Collaboration Stroke Review Group : Meeting the Need for Systematic Reviews in Stroke Care Stroke, March 1, 1995; 26(3): 498 - 502. [Abstract] [Full Text] |
||||
![]() |
M. Yasaka and T. Yamaguchi Immediate Anticoagulation for Intracardiac Thrombus in Acute Cardioembolic Stroke Angiology, November 1, 1992; 43(11): 886 - 892. [Abstract] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |